Cargando…

Astrocyte Signature in Alzheimer’s Disease Continuum through a Multi-PET Tracer Imaging Perspective

Reactive astrogliosis is an early event in the continuum of Alzheimer’s disease (AD). Current advances in positron emission tomography (PET) imaging provide ways of assessing reactive astrogliosis in the living brain. In this review, we revisit clinical PET imaging and in vitro findings using the mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fontana, Igor C., Scarpa, Miriam, Malarte, Mona-Lisa, Rocha, Filipa M., Ausellé-Bosch, Sira, Bluma, Marina, Bucci, Marco, Chiotis, Konstantinos, Kumar, Amit, Nordberg, Agneta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253101/ https://www.ncbi.nlm.nih.gov/pubmed/37296589 http://dx.doi.org/10.3390/cells12111469

Ejemplares similares

Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer’s disease cases
por: Malarte, Mona-Lisa, et al.
Publicado: (2020)

Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brains
por: Malarte, Mona-Lisa, et al.
Publicado: (2022)

Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline
por: Bucci, Marco, et al.
Publicado: (2021)

Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging
por: Murugan, N. Arul, et al.
Publicado: (2019)

Astroglial tracer BU99008 detects multiple binding sites in Alzheimer’s disease brain
por: Kumar, Amit, et al.
Publicado: (2021)

Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer’s disease
por: Carter, Stephen F., et al.
Publicado: (2018)

Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau Fibrils
por: Zhou, Yang, et al.
Publicado: (2021)

Tau PET imaging: present and future directions
por: Saint-Aubert, Laure, et al.
Publicado: (2017)

Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging
por: Chiotis, Konstantinos, et al.
Publicado: (2015)

Dual tracer tau PET imaging reveals different molecular targets for (11)C-THK5351 and (11)C-PBB3 in the Alzheimer brain
por: Chiotis, Konstantinos, et al.
Publicado: (2018)

Spatial Normalization of (18)F-Flutemetamol PET Images Using an Adaptive Principal-Component Template
por: Lilja, Johan, et al.
Publicado: (2019)

Insight into the Binding of First- and Second-Generation PET Tracers to 4R and 3R/4R Tau Protofibrils
por: Li, Junhao, et al.
Publicado: (2023)

Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic
por: Bucci, Marco, et al.
Publicado: (2023)

Tau PET imaging in neurodegenerative tauopathies—still a challenge
por: Leuzy, Antoine, et al.
Publicado: (2019)

In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer’s Brain Tissue
por: Ni, Ruiqing, et al.
Publicado: (2021)

Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer’s Tauopathy
por: Murugan, N. Arul, et al.
Publicado: (2021)

Clinical impact of [(18)F]flutemetamol PET among memory clinic patients with an unclear diagnosis
por: Leuzy, Antoine, et al.
Publicado: (2019)

Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [(18)F]THK5317 PET
por: Jonasson, My, et al.
Publicado: (2019)

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
por: Chiotis, Konstantinos, et al.
Publicado: (2023)

Assessment of Tau Pathology as Measured by (18)F-THK5317 and (18)F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer’s Disease
por: Colato, Elisa, et al.
Publicado: (2021)

Associations between different tau-PET patterns and longitudinal atrophy in the Alzheimer’s disease continuum: biological and methodological perspectives from disease heterogeneity
por: Mohanty, Rosaleena, et al.
Publicado: (2023)

Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding
por: Lemoine, Laetitia, et al.
Publicado: (2018)

Correction: Associations between different tau‑PET patterns and longitudinal atrophy in the Alzheimer’s disease continuum: biological and methodological perspectives from disease heterogeneity
por: Mohanty, Rosaleena, et al.
Publicado: (2023)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Chiotis, Konstantinos, et al.
Publicado: (2021)

Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
por: Chiotis, Konstantinos, et al.
Publicado: (2016)

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease
por: Rodriguez-Vieitez, Elena, et al.
Publicado: (2016)

Regional tau deposition measured by [(18)F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease
por: Saint-Aubert, Laure, et al.
Publicado: (2016)

[(18)F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer’s disease
por: Chiotis, Konstantinos, et al.
Publicado: (2020)

Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains
por: Lemoine, Laetitia, et al.
Publicado: (2017)

Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism
por: Smailovic, Una, et al.
Publicado: (2020)

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Bischof, Gérard N, et al.
Publicado: (2021)

PET Tracers for Clinical Imaging of Breast Cancer
por: Peñuelas, Iván, et al.
Publicado: (2012)

Microfluidics for Synthesis of Peptide-Based PET Tracers
por: Liu, Yang, et al.
Publicado: (2013)

Advanced Tracers in PET Imaging of Cardiovascular Disease
por: Li, Yesen, et al.
Publicado: (2014)

Stroke detection with 3 different PET tracers
por: Dundar, Ayca, et al.
Publicado: (2019)

Emerging PET Tracers in Cardiac Molecular Imaging
por: Singh, Shashi Bhushan, et al.
Publicado: (2023)

Imidazoline-I2 PET Tracers in Neuroimaging
por: Parker, Christine A., et al.
Publicado: (2023)

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors
por: Helgebostad, Rasmus, et al.
Publicado: (2022)

Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue
por: Lemoine, L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1pbhin6tubbmeqeogcdcv2m8dr